CoChat

Effects by daily long term provision of ghrelin to unselected weight‐losing cancer patients: A randomized double‐blind study

Lundholm, Kent, Gunnebo, Lena, Körner, Ulla, Iresjö, Britt‐Marie, Engström, Cecilia, Hyltander, Anders, Smedh, Ulrika, Bosaeus, Ingvar · 2010 · Cancer
Cited by 102

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The short‐term provision of ghrelin to patients with cancer indicates that there may be benefits from long‐term provision of ghrelin for the palliative treatment of weight‐losing cancer patients. This hypothesis was evaluated in a randomized, double‐blind, phase 2 study. METHODS: Weight‐losing cancer patients with solid gastrointestinal tumors were randomized to receive either high‐dose ghrelin treatment (13 μg/kg daily; n = 17 patients) or low‐dose ghrelin treatment (0.7 μg/kg daily; n = 14 patients) for 8 weeks as a once‐daily, subcutaneous injections. Appetite was scored on a visual analog scale; and food intake, resting energy expenditure, and body composition (dual x‐ray absorpitometry) were measured before the start of treatment and during follow‐up. Serum levels of ghrelin, insulin, insulin‐like growth factor 1, growth hormone (GH), triglycerides, free fatty acids, and glucose were measured. Health‐related quality of life, anxiety, and depression were assessed by using standardized methods (the 36‐item Short Form Health Survey and the Hospital Anxiety and Depression Scale). Physical activity, rest, and sleep were measured by using a multisensor body monitor. RESULTS: Treatment groups were comparable at inclusion. Appetite scores were increased significantly by high‐dose ghrelin analyzed both on an intent‐to‐treat basis and according to the protocol. High‐dose ghrelin reduced the loss of whole body fat (P < .04) and serum GH (P < .05). There was a trend for high‐dose ghrelin to improve energy balance (P < .07; per protocol). Otherwise, no statistically significant differences in outcome variables were observed between the high‐dose and low‐dose groups. Adverse effects were not observed by high‐dose ghrelin, such as serum levels of tumor markers (cancer antigen 125 [CA 125], carcinoembryonic antigen, and CA 19‐9). CONCLUSIONS: The current results suggested that daily, long‐term provision of ghrelin to weight‐losing cancer patients with solid tumors supports host metabolism, improves appetite, and attenuates catabolism. Cancer 2010. © 2010 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.24917

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Lundholm, K., Gunnebo, L., Körner, U., Iresjö, B., Engström, C., Hyltander, A., Smedh, U., & Bosaeus, I.
Venue
Cancer
Publisher
Wiley
Published
2010-04-06
Volume
116
Issue
8
Pages
2044-2052
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2015904924
Cited by
102
References
4
FWCI
3.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.